Skip to main content
Nehal Lakhani, MD, Oncology, Grand Rapids, MI

NehalJagdishLakhaniMD

Oncology • Grand Rapids, MI

Physician

Join to view full profile

Dr. Lakhani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lakhani's full profile

Already have an account?

  • Office

    5800 Foremost Dr SE Ste 100
    Grand Rapids, MI 49546
    Phone+1 616-954-5554

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
  • Corewell Health – Grand Rapids/Michigan State University
    Corewell Health – Grand Rapids/Michigan State UniversityResidency, Internal Medicine, 2005 - 2008
  • Baroda Medical College
    Baroda Medical CollegeClass of 2000

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2005 - 2026
  • PA State Medical License
    PA State Medical License 2011 - 2012
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy of Selpercatinib in RET-Altered Thyroid Cancers  
    Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine

Abstracts/Posters

  • A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
    Nehal Lakhani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

  • Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
  • Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
  • Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020

Press Mentions

  • Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
    Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingMay 25th, 2023
  • (ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
    (ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination TherapiesMay 31st, 2020
  • ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
    ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid TumorsNovember 7th, 2018
  • Join now to see all

Other Languages

  • Hindi

Dr. Nehal Lakhani, Dr. Nehal Lakhani, MD, Dr. N Lakhani, Dr. Nehal Jagdish Lakhani